NCT02850302View on ClinicalTrials.gov

Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 8, 2016

Primary Completion Date

November 8, 2016

Study Completion Date

October 31, 2017

Conditions
Breast Neoplasms
Interventions
OTHER

PET with FDG

A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.

OTHER

Tumor exome analysis

A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.

Trial Locations (1)

21079

CGFL, Dijon

All Listed Sponsors
lead

Centre Georges Francois Leclerc

OTHER

NCT02850302 - Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET | Biotech Hunter | Biotech Hunter